{
    "clinical_study": {
        "@rank": "6503", 
        "arm_group": [
            {
                "arm_group_label": "routine prophylaxis", 
                "arm_group_type": "Active Comparator", 
                "description": "In this group, CSA plus MMF and MTX adopted as prevention of GVHD."
            }, 
            {
                "arm_group_label": "ATG prophylaxis", 
                "arm_group_type": "Experimental", 
                "description": "In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD"
            }
        ], 
        "brief_summary": {
            "textblock": "Age is a risk factor for graft-versus-host disease (GVHD) after human leukocyte antigen\n      (HLA)-matched sibling allogeneic stem cell transplantation (allo-SCT). The incidence of\n      acute GVHD is significantly higher in patients at 40 years of age or more than those at 18\n      to 39 years of age after allo-SCT. It was found that Anti-thymocyte globulins can be used\n      for prophylaxis of both acute and chronic GVHD after allo-SCT.Prophylaxis of GVHD using ATG\n      in patients at 40 years of age or more in matched sibling allo-SCT settings might\n      significantly decrease the incidence of acute and chronic GVHD and the incidence of late\n      effect after transplantation."
        }, 
        "brief_title": "Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Leukemia, GVHD, ATG, Transplantation", 
        "condition_browse": {
            "mesh_term": [
                "Graft vs Host Disease", 
                "Leukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prophylaxis for GVHD included CSA, MTX and MMF\u00b1ATG. In the trial group, CSA was started\n      intravenously on day -1, at the dosage of 3 mg/kg, and switched to oral formulation as soon\n      as the patient was able to take medication after engraftment. The dosage was adjusted to\n      maintain a trough blood level of 200-300ng/ml. MMF was administered orally, 0.25g every 12\n      hours, from day -1 before transplantation to day 30 after transplantation. The dosage of MTX\n      was 15 mg/m2, administered i.v. on day 1, and 10 mg/m2 on days 3, 6, and 11 after\n      transplantation. ATG (Thymoglobulin 2.5mg/kg per day i.v.) on days -2 through -1. In the\n      control group, CSA was started intravenously on day -1, at the dosage of 3 mg/kg, and\n      switched to oral formulation as soon as the patient was able to take medication after\n      engraftment. The dosage was adjusted to maintain a trough blood level of 200-300ng/ml. MMF\n      was administered orally, 0.25g every 12 hours, from day -1 before transplantation to day 30\n      after transplantation. The dosage of MTX was 15 mg/m2, administered i.v. on day 1, and 10\n      mg/m2 on days 3, 6, and 11 after transplantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Standard-risk of recipients with hematological malignancies (including AML-CR1,\n             ALL-CR1, CML-CP, MDS-RA, RARS,RCMD,RAEB-1); age from 40 to 60; having HLA-matched\n             sibling donor; Eastern Cooperative Oncology Group (ECOG)\u22641, ejection fraction\n             (EF)\u226550%; bilirubin\u226435\u00b5mol/L; AST, and ALT lower than or equall to two-fold\n             baseline;creatinie\u2264130\u00b5mol/L.\n\n        Exclusion Criteria:\n\n          -  Active, uncontrolled infection; severe allergy to ATG, including shock or laryngeal\n             edema; secondary stem cell transplant recipient; haplidentical recipients; matched\n             unrelated donor recipients; non-myeloablative condioning regimen recipients; EF<50%;\n             bilirubin>35\u00b5mol/L; AST, and ALT higher than two-fold baseline; creatinie>130\u00b5mol/L."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856803", 
            "org_study_id": "2013-08"
        }, 
        "intervention": {
            "arm_group_label": [
                "routine prophylaxis", 
                "ATG prophylaxis"
            ], 
            "intervention_name": "anti thymoglobulin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antilymphocyte Serum"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 14, 2013", 
        "location": {
            "contact": {
                "email": "pk200608@126.com", 
                "last_name": "ying-jun chang, MD,PHD"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100044"
                }, 
                "name": "Peking university people's hospital"
            }, 
            "investigator": {
                "last_name": "Xiao-jun huang, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies", 
        "overall_contact": {
            "email": "pk200608@126.com", 
            "last_name": "Ying-Jun Chang, MD,PhD", 
            "phone": "86-10-88324671"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of acute GVHD, and chronic GVHD", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856803"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University People's Hospital", 
            "investigator_full_name": "Xiaojun Huang", 
            "investigator_title": "director of peking university institute of hematology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Peking University People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}